Deutsche Bank Turns Bullish on CoreWeave
Deutsche Bank upgrades CoreWeave to Buy, sets a $140 price target, and highlights strong growth potential through 2026.
Already have an account? Sign in.
Deutsche Bank upgrades CoreWeave to Buy, sets a $140 price target, and highlights strong growth potential through 2026.
Vanda Pharmaceuticals’ BYSANTI (milsaperidone) receives FDA approval as a new atypical antipsychotic for bipolar I manic/mixed episodes and schizophrenia in adults. Launch expected Q3 2026 with strong patent protection until 2044.
OpenAI scales back its massive compute spending target to ~$600B by 2030 (from earlier $1.4T talk), eyes over $280B revenue, closes in on $100B+ funding round with Nvidia, Amazon, and more.
First Citizens BancShares, fresh off buying Silicon Valley Bank, is hunting for deals like a possible KeyCorp takeover to quickly surpass $250 billion in assets and handle tougher rules with more scale.